Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP707 for borderline personality disorder
2024-510873-11-00Phase 2Authorised
- Sponsor
- Apurano Pharmaceuticals GmbH
- Start
- Apr 2026
- Modality
- Small Molecules, Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in borderline personality disorder (BPD) comparing AP707 with Placebo (2 arms). Planned start Apr 2026; status: authorised.
02
Drugs
adezunap
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on 2024-510873-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510873-11-00.